MARKET

CYCN

CYCN

Cyclerion Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.87
+0.07
+1.21%
After Hours: 6.00 +0.13 +2.21% 17:15 07/02 EDT
OPEN
5.92
PREV CLOSE
5.80
HIGH
6.00
LOW
5.73
VOLUME
118.18K
TURNOVER
--
52 WEEK HIGH
14.83
52 WEEK LOW
1.690
MARKET CAP
162.92M
P/E (TTM)
-1.5223
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CYCN stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

CYCN News

More
How R&D Expenses Can Help You Pick Outperforming Stocks
Seeking Alpha - Article · 1d ago
INO, HEPA, HTZ and SINT among midday movers
Seeking Alpha - Article · 06/23 16:42
Cyclerion to Host Webcast Investor Event on July 9, 2020
GlobeNewswire · 06/18 21:01
The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset
Simply Wall St. · 05/22 12:52
Cyclerion Updates Corporate Progress
GlobeNewswire · 04/10 12:00
Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock?
Simply Wall St. · 03/23 11:50
BTU, VVUS, TSLA and ZIOP among midday movers
Seeking Alpha - Article · 02/05 17:45
DDD, NVTA among premarket gainers
Seeking Alpha - Article · 01/13 14:27

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About CYCN

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
More

Webull offers kinds of Cyclerion Therapeutics Inc stock information, including NASDAQ:CYCN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCN stock methods without spending real money on the virtual paper trading platform.